Join our email list to stay up to date on the latest Amyloidosis news.

ARC welcomed Jan Griffin, MD, amyloidosis cardiologist at the Medical University of South Carolina. Dr. Griffin discussed how ATTR affects the heart and explored advances in treatments for ATTR-CM.

She explained the medications currently available, how they work, how doctors know if they’re helping, and what new treatments are coming in the future.

The webinar concluded with a Q&A session.

Original Presentation Date:
June 10, 2025.

Download the Slides

 

0:00 — Welcome

3:47 — Introduction

6:07 — ATTR Cardiac Amyloidosis Overview

TTR Stabilizers

10:58 — Vyndamax® / Vyndaqel® (tafamidis)

14:53 — Attruby™ (acoramidis)

TTR Silencers

19:18 — Amvuttra® (vutrisiran)

22:31 — Eplontersen

Gene Editing

25:14 — Nex-z (NTLA-2001)

29:44 — MAGNITUDE Study

Depleting TTR

31:54 — ALXN2220 (NI006)

36:08 — Coramitug (NNC6019/PRX004)

Prevention

37:55 — ACT-EARLY Trial

39:42 — Summary of ATTR Cardiac Therapies

40:53 — Combination Therapy

45:50 — How to Choose Initial Therapy

49:16 — Adjunctive Therapies for Heart Failure

53:52 — ARC Summary of Approved Treatments for ATTR-CM

54:47 — Q&A Session

55:03 — If I’m on one treatment, how should I go about considering other treatments?

57:36 — How often is Amvuttra® (vutrisiran) administered?

57:57 — How does Vitamin A function with reduced TTR?

59:21 — Where and how can I access gene editing treatments?

1:01:00 — When might some of the treatments currently under investigation become available?

1:03:01 — How frequently should I have my biomarkers and medical imaging monitored?

1:04:51 — What are the side effects/risks of taking tafamidis?

1:05:53 — Conclusion

 

Contact ARC:

Call +1 (617) 467-5170

Email ARC at support@arci.org

 

*

*

*









*